Inventiva S.A.

Inventiva S.A. is a clinical-stage biopharmaceutical company focused on developing oral small‑molecule therapies, primarily for metabolic dysfunction‑associated steatohepatitis (MASH). Its main product candidate is lanifibranor, a pan‑PPAR oral small molecule in Phase 3 development, supported by a proprietary discovery engine, a library of pharmacologically relevant molecules and a wholly owned R&D facility; the company previously developed odiparcil and maintained earlier preclinical oncology programs. Key business activities are organized around clinical development, discovery and preclinical research, manufacturing via contract manufacturing organizations, and strategic partnerships. Inventiva conducts global clinical trials and pursues regulatory and commercial collaborations across the United States, Europe, China, Japan and other international markets.

Summary from filing dated 2025-04-15